Back grey_arrow_rt.gif
 
 
J&J looks to end Remicade pact with S-P after Merck merger
 
 
  21 May 2009 www.pharmatimes.com
 
Schering-Plough has confirmed in a filing to US regulators that Johnson & Johnson plans to seek arbitration as to whether it can terminate the firms' marketing agreement covering the rheumatoid arthritis and Crohn's disease blockbuster Remicade now that S-P is merging with Merck & Co.
 
The two companies have a distribution agreement which sees J&J's Centocor unit sell Remicade (infliximab) in the USA, while S-P markets the drug elsewhere. The pact also includes the recently-approved arthritis treatment Simponi (golimumab).
 
The agreement can be terminated if a "change of control" occurred at S-P but the firm and Merck claim that their proposed deal is structured as a reverse merger, allowing S-P to remain as a surviving entity. A lot of cash is at stake as Remicade generated about $2.1 billion in sales for S-P last year.
 
J&J noted that "as its public statements make clear", Merck is acquiring S-P and "the acquisition constitutes a change of control". As such, it triggers the healthcare giant's right to terminate the partnership so J&J will commence arbitration "seeking the return of full rights" to Remicade and golimumab.
 
In the 313-page filing to the US Securities and Exchange Commission, Merck and S-P said in the SEC filing they would "vigorously contest any attempt by Centocor to terminate the distribution agreement". S-P added that "due to the uncertainty surrounding the outcome of any threatened or actual arbitration proceeding...the parties may choose to settle a dispute under mutually agreeable terms".
 
S-P and Merck concluded by saying that any change to the relationship with J&J will not have a "material adverse effect" on the credit agreements that have been put in place to finance the proposed merger.
 
By Kevin Grogan
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org